In oncology, biomarkers that describe the characteristics of a malignancy on different levels (clinical, histological, molecular) and the patient's outcome and treatment response are increasingly integrated into the clinical routine. Extensive screening tools, “omics,” offer incredible opportunities and vast amounts of data. During the last years, the field of “omics” gained a new promising partner, the “radiomics.” Based on radiological imaging, multiple features can be extracted and linked to clinical, genomic, and histopathological data from other sources. Extracted traits describe radiological intensity, shape and texture characteristics and can be analyzed on routinely performed images. These specific radiomic markers and patterns are currently developed for multiple tumor entities, and first studies for squamous cell carcinoma of the head and neck have been initiated.

1.
Lambin P, Rios-Velazquez E, Leijenaar R, Carvalho S, van Stiphout RGPM, Granton P, et al: Radiomics: extracting more information from medical images using advanced feature analysis. Eur J Cancer 2012;48:441-446.
2.
Yip SSF, Aerts HJWL: Applications and limitations of radiomics. Phys Med Biol 2016;61:R150-R166.
3.
Giger ML, Chan H-P, Boone J: Anniversary paper: history and status of CAD and quantitative image analysis: the role of Medical Physics and AAPM. Med Phys 2008;35:5799-5820.
4.
Giger ML, Karssemeijer N, Schnabel JA: Breast image analysis for risk assessment, detection, diagnosis, and treatment of cancer. Annu Rev Biomed Eng 2013;15:327-357.
5.
Gillies RJ, Kinahan PE, Hricak H: Radiomics: images are more than pictures, they are data. Radiology 2016;278:563-577.
6.
Aerts HJWL, Velazquez ER, Leijenaar RTH, Parmar C, Grossmann P, Carvalho S, et al: Decoding tumour phenotype by noninvasive imaging using a quantitative radiomics approach. Nat Commun 2014;5:4006.
7.
Sala E, Mema E, Himoto Y, Veeraraghavan H, Brenton JD, Snyder A, et al: Unravelling tumour heterogeneity using next-generation imaging: radiomics, radiogenomics, and habitat imaging. Clin Radiol 2017;72:3-10.
8.
Kumar V, Gu Y, Basu S, Berglund A, Eschrich SA, Schabath MB, et al: Radiomics: the process and the challenges. Magn Reson Imaging 2012;30:1234-1248.
9.
Diehn M, Nardini C, Wang DS, McGovern S, Jayaraman M, Liang Y, et al: Identification of noninvasive imaging surrogates for brain tumor gene-expression modules. Proc Natl Acad Sci USA 2008;105:5213-5218.
10.
Segal E, Sirlin CB, Ooi C, Adler AS, Gollub J, Chen X, et al: Decoding global gene expression programs in liver cancer by noninvasive imaging. Nat Biotechnol 2007;25:675-680.
11.
Ghosh P, Tamboli P, Vikram R, Rao A: Imaging-genomic pipeline for identifying gene mutations using three-dimensional intra-tumor heterogeneity features. J Med Imaging (Bellingham) 2015;2:041009.
12.
Karlo CA, Di Paolo PL, Chaim J, Hakimi AA, Ostrovnaya I, Russo P, et al: Radiogenomics of clear cell renal cell carcinoma: associations between CT imaging features and mutations. Radiology 2014;270:464-471.
13.
Yu J, Shi Z, Lian Y, Li Z, Liu T, Gao Y, et al: Noninvasive IDH1 mutation estimation based on a quantitative radiomics approach for grade II glioma. Eur Radiol, Epub ahead of print.
14.
Ahmed A, Gibbs P, Pickles M, Turnbull L: Texture analysis in assessment and prediction of chemotherapy response in breast cancer. J Magn Reson Imaging 2013;38:89-101.
15.
Wibmer A, Hricak H, Gondo T, Matsumoto K, Veeraraghavan H, Fehr D, et al: Haralick texture analysis of prostate MRI: utility for differentiating non-cancerous prostate from prostate cancer and differentiating prostate cancers with different Gleason scores. Eur Radiol 2015;25:2840-2850.
16.
Li H, Zhu Y, Burnside ES, Huang E, Drukker K, Hoadley KA, et al: Quantitative MRI radiomics in the prediction of molecular classifications of breast cancer subtypes in the TCGA/TCIA data set. NPJ Breast Cancer 2016;2:16012.
17.
Bhooshan N, Giger ML, Jansen SA, Li H, Lan L, Newstead GM: Cancerous breast lesions on dynamic contrast-enhanced MR images: computerized characterization for image-based prognostic markers. Radiology 2010;254:680-690.
18.
Rose CJ, Mills SJ, O'Connor JPB, Buonaccorsi GA, Roberts C, Watson Y, et al: Quantifying spatial heterogeneity in dynamic contrast-enhanced MRI parameter maps. Magn Reson Med 2009;62:488-499.
19.
Bae JM, Jeong JY, Lee HY, Sohn I, Kim HS, Son JY, et al: Pathologic stratification of operable lung adenocarcinoma using radiomics features extracted from dual energy CT images. Oncotarget 2016;8:523-535.
20.
Coroller TP, Grossmann P, Hou Y, Rios-Velazquez E, Leijenaar RTH, Hermann G, et al: CT-based radiomic signature predicts distant metastasis in lung adenocarcinoma. Radiother Oncol 2015;114:345-350.
21.
Fakhry C, Westra WH, Li S, Cmelak A, Ridge JA, Pinto H, et al: Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. J Natl Cancer Inst 2008;100:261-269.
22.
Ang KK, Harris J, Wheeler R, Weber R, Rosenthal DI, Nguyen-Tân PF, et al: Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med 2010;363:24-35.
23.
Parmar C, Leijenaar RTH, Grossmann P, Rios-Velazquez E, Bussink J, Rietveld D, et al: Radiomic feature clusters and prognostic signatures specific for lung and head & neck cancer. Sci Rep 2015;5:11044.
24.
Parmar C, Grossmann P, Rietveld D, Rietbergen MM, Lambin P, Aerts HJWL: Radiomic machine-learning classifiers for prognostic biomarkers of head and neck cancer. Front Oncol 2015;5:272.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.